Research Output Journal of Public Health and Medicine 6(1):87-91, 2026

ROJPHM ISSN ONLINE: 1115-9715

https://rojournals.org/roj-public-health-and-medicine/ ISSN PRINT: 1115-6147

https://doi.org/10.59298/ROJPHM/2026/618791

RTS, S/AS01 Malaria Vaccine Implementation: Efficacy, Safety, and Population-Level Impact in Endemic Regions

Otieno Karanja J.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Malaria remains the leading cause of morbidity and mortality in sub-Saharan Africa, prompting the development and deployment of vaccination strategies. RTS, S/AS01 was the first malaria vaccine recommended by WHO for children in endemic regions, targeting Plasmodium falciparum. This review aimed to critically assess the efficacy, safety profile, and population-level impact of RTS, S/AS01 vaccine implementation in malaria-endemic settings. A systematic literature search was conducted across peer-reviewed journals and WHO reports focusing on Phase III trials, pilot implementation programs, and post-marketing surveillance studies published within the past decade. RTS, S/AS01 demonstrated moderate efficacy against clinical malaria (approximately 30-40%) and severe malaria (around 30%) following a four-dose schedule in children aged 5-17 months; efficacy wanes over time but is partially restored by a fourth booster dose. Safety data indicated a generally favorable profile, with febrile seizures being the most common vaccine-related adverse event; signals of increased meningitis and cerebral malaria incidence have been observed but are inconclusive and require further post-implementation surveillance. Population-level modeling and early pilot program data revealed reductions in malaria cases and hospitalizations, though challenges such as vaccine hesitancy, logistical implementation issues, and ensuring equitable coverage persist. RTS, S/AS01 offers a valuable addition to malaria control in endemic regions with proven benefits despite partial protection and some safety concerns. Continued monitoring and tailored implementation strategies are essential to maximize public health impact.

Keywords: RTS, S/AS01, Malaria vaccine, Efficacy, Safety, Endemic regions

INTRODUCTION

Malaria, primarily caused by Plasmodium falciparum, remains a critical public health challenge, especially in sub-Saharan Africa, where it causes significant childhood morbidity and mortality. Despite ongoing vector control efforts and chemoprophylaxis, transmission persists due to complex parasite biology and socio-economic factors that undermine eradication efforts. The demand for an effective vaccine has been longstanding, given the partial efficacy of existing interventions and the rise of insecticide and drug resistance [1–3].

RTS,S/AS01 is the first malaria vaccine to receive WHO recommendation for routine use in children living in moderate-to-high transmission areas [4]. The vaccine targets the circumsporozoite protein (CSP) of P. falciparum to induce humoral and cellular immunity, aiming to prevent early liver-stage infection and subsequent clinical disease. Its introduction marks a milestone in malaria vaccine development, yet the complexity of malaria immunology and epidemiology necessitates comprehensive evaluation of its real-world performance, safety, and population-level benefits [5].

This review aims to critically synthesize current evidence on RTS, S/AS01 vaccine efficacy, safety, and impact following its implementation in endemic regions, to inform future research, policy, and programmatic strategies.

Molecular Mechanism and Biochemistry of RTS, S/AS01 Vaccine

The RTS,S/AS01 vaccine comprises a recombinant fusion protein, RTS,S, containing a portion of the P. falciparum circumsporozoite protein (CSP) linked to the hepatitis B surface antigen, combined with the AS01 adjuvant system

that enhances immune responses [6, 7]. The CSP is a critical molecule expressed on sporozoites, facilitating hepatocyte invasion; antibodies against CSP block parasite entry and development, thereby preventing symptomatic infection [8].

Preclinical studies demonstrated strong immunogenicity and induction of both humoral and CD4+ T-cell responses, essential for parasite clearance during the pre-erythrocytic stage. Phase I and II trials confirmed dose-dependent antibody titers and cellular immunity, with adjuvant AS01 markedly increasing efficacy compared to earlier formulations. However, the vaccine induces partial immunity, reflecting the complex immune evasion strategies of P. falciparum and antigenic variability [9].

Limitations include the modest longevity of protective immunity, necessitating a four-dose schedule with booster administration. Immunological studies reveal waning antibody titers over months post-primary vaccination, consistent with observed decreases in clinical protection. Immune correlates of protection remain incompletely defined, complicating optimization of dosing regimens and adjuvant design [10]. RTS,S/AS01 stimulates targeted immune responses against CSP, conferring moderate, time-limited protection against P. falciparum infection. Further refinement of immunogenicity and durability is needed to enhance vaccine efficacy.

Analytical and Experimental Methods for Efficacy and Safety Assessment

Efficacy evaluations of RTS,S/AS01 have been extensively conducted through randomized controlled trials, specifically the pivotal Phase III study enrolling over 15,000 children aged 6 weeks to 17 months across multiple African countries. The trials employed clinical endpoints including time to first or only episodes of clinical malaria, severe malaria, and malaria-associated hospitalizations, with a follow-up period extending up to 48 months post-vaccination [11].

Efficacy analyses incorporated intention-to-treat and per-protocol populations, revealing variable vaccine efficacy. In children aged 5-17 months, the four-dose regimen achieved approximately 36% reduction in clinical malaria incidence, while infants (6-12 weeks) displayed lower efficacy (~25%). A booster dose at 18 months restored partial efficacy, though waning was observed, demonstrating challenges in sustaining long-term immunity [12].

Safety assessments involved monitoring for solicited and unsolicited adverse events (AEs), serious adverse events (SAEs), and mortality. Febrile seizures were identified as the most frequent vaccine-related AE, particularly following the third dose, but were transient with complete recovery reported. Signals of increased incidence of meningitis and cerebral malaria in vaccinated children emerged, though causality was not established due to lack of consistent temporal or etiological patterns and geographic clustering [13].

Post-marketing surveillance and pilot implementation studies emphasize ongoing safety monitoring to discern rare adverse events. Methodological strengths include large sample sizes and multicentric design, whereas limitations encompass heterogeneity in transmission intensity among sites and the difficulty in attributing causality for certain safety signals. Current experimental methodologies robustly delineate the moderate vaccine efficacy and generally acceptable safety profile of RTS,S/AS01, highlighting the need for continued surveillance and optimization of vaccination schedules.

Clinical and Pathophysiological Implications of RTS,S/AS01 Vaccine Implementation

Clinical implications of RTS,S/AS01 deployment include measurable reductions in malaria episodes, severe disease, and associated hospitalizations, translating to decreased childhood morbidity and potential mortality reduction in endemic regions. Nonetheless, vaccine efficacy is partial, and the protection duration limited, necessitating integration with existing malaria control interventions such as insecticide-treated nets and chemoprophylaxis [14].

Population-level impact models predict substantive declines in malaria burden, especially when vaccine coverage is prioritized in high-incidence locales. Pilot programs in Ghana, Kenya, and Malawi reaffirm these projections, demonstrating vaccine acceptance, reduced malaria cases, and feasibility of incorporating RTS,S/AS01 into routine immunization schedules. However, vaccine-induced immunity does not fully prevent infection or transmission, underscoring the vaccine's role as a complementary tool rather than a standalone solution [15].

Safety concerns regarding febrile seizures and potential increases in meningitis and cerebral malaria warrant vigilance and risk-benefit assessment. Importantly, all-cause mortality data have shown a sex-specific imbalance with higher mortality among vaccinated girls in some contexts, though underlying causes remain undetermined and subject to further study [16]. RTS,S/AS01 implementation offers clinical benefits by decreasing malaria-associated morbidity, with ongoing assessment required to mitigate safety risks and optimize programmatic integration.

Therapeutic and Translational Aspects in Malaria Control

Beyond direct protective efficacy, RTS,S/AS01 represents a translational advance informing malaria vaccination strategies and immunological approaches to complex parasitic diseases. The partial efficacy signals that while CSP is a valid target, vaccine constructs must address antigenic diversity, immune evasion, and durability challenges to improve outcomes [17].

Combination strategies integrating RTS,S/AS01 vaccination with chemoprevention or vector control measures have shown synergistic effects in reducing malaria transmission and disease burden. The vaccine's implementation

has also stimulated interest in second-generation vaccines with enhanced efficacy, such as R21/Matrix-M, and mRNA vaccine platforms [18].

Operational research highlights barriers to vaccine delivery, including cold chain requirements, multi-dose scheduling, community sensitization to counter vaccine hesitancy, and health system capacity constraints. Tailored approaches encompassing culturally appropriate education and improved infrastructure are critical for maximizing impact [19].

Thus, RTS,S/AS01 serves both as a practical tool and a scientific foundation driving innovation in malaria vaccine development and integrated malaria control programs.

Gaps, Controversies, and Future Research Directions

Notable gaps persist in understanding long-term vaccine-induced immunity mechanisms, optimal dosing schedules for sustained protection, and the biological basis for observed adverse events, including meningitis and cerebral malaria. Data heterogeneity across trial sites complicates extrapolation of efficacy and safety outcomes, requiring nuanced regional analyses [20].

Controversy surrounds the statistical significance and interpretation of safety signals, with WHO and regulatory authorities advocating for ongoing phase IV surveillance to resolve uncertainties without undermining public confidence. Additionally, challenges in vaccine acceptance, access equity, and operational sustainability in resource-limited settings impede maximal utilization [21].

Future research priorities include the development of next-generation vaccines with improved efficacy and durability, refined immunological correlates for protection, and integrated vaccination strategies within broader malaria control frameworks. Enhanced pharmacovigilance systems and context-specific implementation science are essential to address hesitancy and logistical challenges. While RTS,S/AS01 signifies a landmark achievement, advancing malaria vaccination will require continuous evidence generation, multidisciplinary collaboration, and adaptive policy measures.

CONCLUSION

The RTS,S/AS01 malaria vaccine has demonstrated moderate efficacy in reducing clinical and severe malaria in children in endemic regions, with protection waning over time but partially restored by booster dosing. Safety profiles are largely acceptable, with febrile seizures being the predominant adverse event; although signals for meningitis and cerebral malaria require further investigation, current evidence underscores an overall favorable benefit-risk balance. Population-level studies and pilot program data highlight meaningful reductions in malaria burden, affirming the vaccine's role as a valuable addition to existing control measures. However, challenges including vaccine hesitancy, implementation logistics, and equity of access remain. Quality of evidence is robust in clinical trial contexts but limited in long-term real-world surveillance, emphasizing the need for ongoing monitoring. Sustained investment in phase IV safety surveillance and tailored community engagement strategies is recommended to optimize RTS,S/AS01 implementation and maximize public health impact.

REFERENCES

1. Erisa, K., Raphael, I., Ugwu, O.P.C., Alum, E.U.: Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. 1, 101–108 (2023)
2. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
3. Ogbonnia Egwu, C., Aloke, C., Chukwu, J., Agwu, A., Tsamesidis, I., E Offor, C., Ajuka Obasi, N., Aja, P.M.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
4. Merle, C.S., Badiane, N.A., Affoukou, C.D., Affo, S.Y., Djogbenou, S.L., Hounto, A., Kompaore, S.C.B., Ouedraogo, I., Ateba, M.J., Njoh, A.A., Bomba, D., Tchokfe, S.N., Ali, I.M., Camara, F., Mbodj, M., Sosler, S., Rono, J., Noonan, L., Venu, M., Tanko, M.N., Gyan, T., Gyapong, M., Nante, J.E., Intchala, H.I., Camara, M.B., Cisse, G., Loua, J.E., Jalang'o, R., Milligan, P., Scott, S., Baker, K., Sande, J., Mhone, B.L., Kone, A., Coulibaly, Y., Diarra, I., Tchouatieu, A.M., Aliaprieto, M., Diallo, I.G., Abou, Y., Assan, A.N., Jibril, H., Nmep, N., Eze, N.C., Bakunawa, G.B., Shekarau, E., Nikau, J., Gordon, S., Wilskie, E.A., Bawa, J., Badiane, N.A., Sturm-Ramirez, K., Kidwang, J.P., Sene, D., Nabykaly, J.S., Abdoulaye, K.A., Diar, M.S.I., Addi, A.M., Hennig, B.J., Yahouedo, G.A., Kolley, O., Fofana, S., Atcha-Oubou, M.N., Djobo, H.L., Mbaye, R., Ousmane, S.Y., Ndiaye, J.L.A., Amadou, S.E.C., Mbaye, I.M., Sall, F.B., Fatoudiop, N., Bakhoum, L.N., Diouf, E.H.M.B., Almamy Youssouph, L.Y., Ndiaye, K., Amankwa, B., Ong, L., Oh, C., Wirngo, B., Kung, L., Hedje, J., Tuitai, L., Efe-Aluta, O., Magafu, M., Ntabangana, S., Kande, M., Okine, R., Hamel, M., Walldorf, J., Furrer, E., Kelleher, K., Lindsey, W.U., Takamiya, M., Bergstrom, C.: Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission:

workshop meeting report. Malar J. 22, 1–14 (2023). https://doi.org/10.1186/S12936-023-04657-5/FIGURES/3

5. Laurens, M.B.: RTS,S/AS01 vaccine (Mosquirix™): an overview. Hum Vaccin Immunother. 16, 480 (2019). https://doi.org/10.1080/21645515.2019.1669415
6. Arora, N., Anbalagan, L.C., Pannu, A.K.: Towards eradication of Malaria: Is the who's RTS,S/AS01 vaccination effective enough? Risk Manag Healthc Policy. 14, 1033–1039 (2021). https://doi.org/10.2147/RMHP.S219294
7. Ainebyoona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.C., Uti, D.E., Alum, B.N, Echegu, D.A. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication (2025). Ethiopian Journal of Health Sciences, 2025; 35(3): 205-217. doi: 10.4314/ejhs.v35i3.9. PMID: 40717722; PMCID: PMC12287706.
8. Osei-Tutu, L., Kariuki, S.K., Lee, C.K., Fabre, R., Bii, D.K., Adjei, S., Oneko, M., Attobrah Sarfo, M.A., Ockenhouse, C.F., Schuerman, L., Buabeng, P.B.Y., Bakari, A., Atieno, C., Kotoh-Mortty, M.F., Otieno, K., Ntiamoah, Y., Sang, T., Bollaerts, A., Westercamp, N., Ansong, D., Agbenyega, T., Samuels, A.M., Ofori-Anyinam, O.: Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial. Lancet Glob Health. 13, e1723–e1736 (2025). https://doi.org/10.1016/S2214-109X(25)00272-4
9. Björkman, A., Benn, C.S., Aaby, P., Schapira, A.: RTS,S/AS01 malaria vaccine—proven safe and effective? Lancet Infect Dis. 23, e318–e322 (2023). https://doi.org/10.1016/S1473-3099(23)00126-3
10. Haine, V., Oneko, M., Debois, M., Ndeketa, L., Agyapong, P.D., Boahen, O., Harrison, S.B.E., Adeniji, E., Kaali, S., Kayan, K., Owusu-Agyei, S., French, N., Kariuki, S., Devadiga, R., Ogutu, B., Ansah, N.A., Orsini, M., Ansah, P.O., Maleta, K., Ong'echa, J.M., Phiri, V.K., Mzanga, P., Jere, T.M., Azongo, D.K., Mategula, D., Orimbo, J., Oduro, A.R., Otieno, W., Kaburise, M.B., Ababio, L.O., Sifuna, P.M., Amoit, S.K., Olewe, F., Oyieko, J.N., Achieng Oguk, E., Guerra Mendoza, Y., Awuni, D., Sing'oei, V., Onyango, I., Schuerman, L., Ochieng, B.O., Okoth, G.O., Nyangulu, W., Cherop, R.Y., Odera-Ojwang, P., Cravcenco, C., Chipatala, R., Roman, F., Savic, M., Asante, K.P.: Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study. Lancet Glob Health. 13, e995–e1005 (2025). https://doi.org/10.1016/S2214-109X(25)00096-8
11. Hogan, A.B., Winskill, P., Ghani, A.C.: Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study. PLoS Med. 17, e1003377 (2020). https://doi.org/10.1371/JOURNAL.PMED.1003377
12. Zoa, J.A., Njemguie Linjouom, R.M., Nyangono Ndongo, M., Nkeck, J.R.: Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials. PLOS Global Public Health. 5, e0004387 (2025). https://doi.org/10.1371/JOURNAL.PGPH.0004387
13. Grant, J., Gyan, T., Agbokey, F., Webster, J., Greenwood, B., Asante, K.P.: Challenges and lessons learned during the planning and early implementation of the RTS,S/AS01E malaria vaccine in three regions of Ghana: a qualitative study. Malar J. 21, (2022). https://doi.org/10.1186/S12936-022-04168-9
14. Malaria vaccines (RTS,S and R21), https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
15. Hill, J., Bange, T., Hoyt, J., Kariuki, S., Jalloh, M.F., Webster, J., Okello, G.: Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective. Lancet Glob Health. 12, e672–e684 (2024). https://doi.org/10.1016/S2214-109X(24)00013-5
16. Osoro, C.B., Ochodo, E., Kwambai, T.K., Otieno, J.A., Were, L., Sagam, C.K., Owino, E.J., Kariuki, S., ter Kuile, F.O., Hill, J.: Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. BMJ Glob Health. 9, e014719 (2024). https://doi.org/10.1136/BMJGH-2023-014719
17. Kelly, S.L., Malinga, J., Penny, M.A., Nawaz, S., Thompson, H., Gordon, S., Winskill, P., Hogan, A., Mulongeni, P., Verity, B., Ghani, A.: Comparing modelled impact and cost-effectiveness estimates for the RTS,S/AS01 malaria vaccine with evaluation results observed in phased pilot introductions PATH, Seattle, USA EXECUTIVE SUMMARY Overall assessment.
18. Björkman, A., Benn, C.S., Aaby, P., Schapira, A.: RTS,S/AS01 malaria vaccine—proven safe and effective? Lancet Infect Dis. 23, e318–e322 (2023). https://doi.org/10.1016/S1473-3099(23)00126-3
19. Yihunie, W., Abebe, D., Kebede, B., Tegegne, B.A., Getachew, M., Aschale, Y., Belew, H., Bahiru, B.: Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized

Controlled Trials in Infants, Children, and Adults. Clin Pharmacol. 15, 21–32 (2023). https://doi.org/10.2147/CPAA.S400155
20. Dimala, C.A., Kika, B.T., Kadia, B.M., Blencowe, H.: Current challenges and proposed solutions to the effective implementation of the RTS, S/ AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review. PLoS One. 13, (2018). https://doi.org/10.1371/JOURNAL.PONE.0209744
21. Ekpang II, J. E., Ekpang, P. O., Ainebyoona, C., Nwagu, K. E., Nwuruku, O. A., & Muhammad, K. (2025). Toward an ethical future for orphan drugs: balancing access, affordability, and innovation. *Journal of Medical Economics*, 1–24. https://doi.org/10.1080/13696998.2025.2577514

CITE AS: Otieno Karanja J. (2026). RTS, S/AS01 Malaria Vaccine Implementation: Efficacy, Safety, and Population-Level Impact in Endemic Regions. Research Output Journal of Public Health and Medicine 6(1):87-91. https://doi.org/10.59298/ROJPHM/2026/618791